MXPA04007310A - Idraparinux(sanorg 34006) para tratamiento y profilaxis secundaria de eventos tromboembolicos venosos en pacientes con trombosis venosa profunda. - Google Patents
Idraparinux(sanorg 34006) para tratamiento y profilaxis secundaria de eventos tromboembolicos venosos en pacientes con trombosis venosa profunda.Info
- Publication number
- MXPA04007310A MXPA04007310A MXPA04007310A MXPA04007310A MXPA04007310A MX PA04007310 A MXPA04007310 A MX PA04007310A MX PA04007310 A MXPA04007310 A MX PA04007310A MX PA04007310 A MXPA04007310 A MX PA04007310A MX PA04007310 A MXPA04007310 A MX PA04007310A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methyl
- sanorg
- sulfo
- tri
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 50
- 206010051055 Deep vein thrombosis Diseases 0.000 title claims abstract description 17
- 206010047249 Venous thrombosis Diseases 0.000 title claims abstract description 17
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 10
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 title claims description 38
- 208000004043 venous thromboembolism Diseases 0.000 claims abstract description 18
- 239000002253 acid Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 14
- 229960005080 warfarin Drugs 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 13
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
- 208000034158 bleeding Diseases 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 11
- 230000036470 plasma concentration Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000006866 deterioration Effects 0.000 description 8
- 229920000669 heparin Polymers 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000001732 thrombotic effect Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229960000610 enoxaparin Drugs 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- AJBMORBNKXNZSF-COSHMZDQSA-N (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxy-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2r,3r,4s,5r,6r)-3,4 Chemical compound OS(=O)(=O)O[C@@H]1[C@@H](OS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS(O)(=O)=O)O4)OC)[C@H](O3)C(O)=O)OC)[C@@H](COS(O)(=O)=O)O2)OS(O)(=O)=O)[C@H](C(O)=O)O1 AJBMORBNKXNZSF-COSHMZDQSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000001858 anti-Xa Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011283 initial treatment period Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003513 popliteal vein Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02075374 | 2002-01-29 | ||
| PCT/EP2003/000696 WO2003063881A1 (en) | 2002-01-29 | 2003-01-23 | Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04007310A true MXPA04007310A (es) | 2004-10-29 |
Family
ID=27635850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04007310A MXPA04007310A (es) | 2002-01-29 | 2003-01-23 | Idraparinux(sanorg 34006) para tratamiento y profilaxis secundaria de eventos tromboembolicos venosos en pacientes con trombosis venosa profunda. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7709463B2 (enExample) |
| EP (1) | EP1471924B1 (enExample) |
| JP (1) | JP4870907B2 (enExample) |
| CN (1) | CN1622813A (enExample) |
| AR (1) | AR038320A1 (enExample) |
| AT (1) | ATE323497T1 (enExample) |
| AU (1) | AU2003205664B2 (enExample) |
| BR (1) | BR0307196A (enExample) |
| CA (1) | CA2472957C (enExample) |
| CY (1) | CY1107661T1 (enExample) |
| DE (1) | DE60304678T2 (enExample) |
| DK (1) | DK1471924T3 (enExample) |
| EA (1) | EA007204B1 (enExample) |
| ES (1) | ES2262971T3 (enExample) |
| MX (1) | MXPA04007310A (enExample) |
| NO (1) | NO332699B1 (enExample) |
| PE (1) | PE20030855A1 (enExample) |
| PL (1) | PL207144B1 (enExample) |
| PT (1) | PT1471924E (enExample) |
| SI (1) | SI1471924T1 (enExample) |
| TW (1) | TWI281861B (enExample) |
| WO (1) | WO2003063881A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008521903A (ja) * | 2004-12-01 | 2008-06-26 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Ｎ置換されたベンズイミダゾリルＣ−ｋｉｔ阻害剤及びコンビナトリアルベンゾイミダゾールライブラリー |
| US9642822B2 (en) | 2011-05-27 | 2017-05-09 | Children's Medical Center Corporation | Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| BR112022000255A8 (pt) | 2019-07-09 | 2022-03-22 | Optimvia Llc | Métodos para sintetizar polissacarídeos anticoagulantes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378829A (en) * | 1990-04-23 | 1995-01-03 | Akzo N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type |
-
2003
- 2003-01-14 TW TW092100703A patent/TWI281861B/zh not_active IP Right Cessation
- 2003-01-23 ES ES03702514T patent/ES2262971T3/es not_active Expired - Lifetime
- 2003-01-23 AT AT03702514T patent/ATE323497T1/de active
- 2003-01-23 MX MXPA04007310A patent/MXPA04007310A/es active IP Right Grant
- 2003-01-23 WO PCT/EP2003/000696 patent/WO2003063881A1/en not_active Ceased
- 2003-01-23 EA EA200400817A patent/EA007204B1/ru not_active IP Right Cessation
- 2003-01-23 BR BR0307196-0A patent/BR0307196A/pt not_active Application Discontinuation
- 2003-01-23 DE DE60304678T patent/DE60304678T2/de not_active Expired - Lifetime
- 2003-01-23 JP JP2003563570A patent/JP4870907B2/ja not_active Expired - Fee Related
- 2003-01-23 DK DK03702514T patent/DK1471924T3/da active
- 2003-01-23 CN CNA038028123A patent/CN1622813A/zh active Pending
- 2003-01-23 PE PE2003000071A patent/PE20030855A1/es not_active Application Discontinuation
- 2003-01-23 SI SI200330334T patent/SI1471924T1/sl unknown
- 2003-01-23 PL PL370557A patent/PL207144B1/pl unknown
- 2003-01-23 CA CA2472957A patent/CA2472957C/en not_active Expired - Fee Related
- 2003-01-23 EP EP03702514A patent/EP1471924B1/en not_active Expired - Lifetime
- 2003-01-23 PT PT03702514T patent/PT1471924E/pt unknown
- 2003-01-23 AU AU2003205664A patent/AU2003205664B2/en not_active Ceased
- 2003-01-23 US US10/502,706 patent/US7709463B2/en not_active Expired - Fee Related
- 2003-01-28 AR ARP030100237A patent/AR038320A1/es not_active Application Discontinuation
-
2004
- 2004-07-27 NO NO20043195A patent/NO332699B1/no not_active IP Right Cessation
-
2006
- 2006-07-19 CY CY20061101002T patent/CY1107661T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20043195L (no) | 2004-10-29 |
| US20050209175A1 (en) | 2005-09-22 |
| EA200400817A1 (ru) | 2005-02-24 |
| EA007204B1 (ru) | 2006-08-25 |
| PT1471924E (pt) | 2006-09-29 |
| TWI281861B (en) | 2007-06-01 |
| CA2472957A1 (en) | 2003-08-07 |
| CY1107661T1 (el) | 2013-04-18 |
| EP1471924A1 (en) | 2004-11-03 |
| DE60304678D1 (de) | 2006-05-24 |
| PL370557A1 (en) | 2005-05-30 |
| ATE323497T1 (de) | 2006-05-15 |
| CA2472957C (en) | 2011-09-13 |
| HK1072361A1 (en) | 2005-08-26 |
| WO2003063881A1 (en) | 2003-08-07 |
| US7709463B2 (en) | 2010-05-04 |
| BR0307196A (pt) | 2004-11-03 |
| AR038320A1 (es) | 2005-01-12 |
| ES2262971T3 (es) | 2006-12-01 |
| PL207144B1 (pl) | 2010-11-30 |
| AU2003205664B2 (en) | 2008-06-05 |
| SI1471924T1 (sl) | 2006-10-31 |
| PE20030855A1 (es) | 2003-10-11 |
| DE60304678T2 (de) | 2007-04-05 |
| EP1471924B1 (en) | 2006-04-19 |
| CN1622813A (zh) | 2005-06-01 |
| DK1471924T3 (da) | 2006-08-21 |
| NO332699B1 (no) | 2012-12-10 |
| JP4870907B2 (ja) | 2012-02-08 |
| JP2005519919A (ja) | 2005-07-07 |
| TW200302104A (en) | 2003-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dechavanne et al. | Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery | |
| Thery et al. | Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. | |
| Lindmarker et al. | Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis | |
| Eriksson et al. | Thrombosis prophylaxis with low molecular weight heparin in total hip replacement | |
| Torholm et al. | Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study | |
| Bergqvist et al. | Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications | |
| Leyvraz et al. | Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparindihydroergotamine | |
| Buchanan et al. | Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II | |
| MXPA04007310A (es) | Idraparinux(sanorg 34006) para tratamiento y profilaxis secundaria de eventos tromboembolicos venosos en pacientes con trombosis venosa profunda. | |
| Nesvold et al. | Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose-finding study | |
| Wood et al. | Trial of aspirin and RA 233 in prevention of post-operative deep vein thrombosis | |
| DE69832066T2 (de) | Verwendung eines oligosaccharids zur vorbeugung von blutgerinnung in extrakorporalen kreisläufen | |
| Chiapuzzo et al. | The use of low molecular weight heparins for post-surgical deep vein thrombosis prevention in orthopaedic patients | |
| AU2003205664A1 (en) | Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis | |
| HK1072361B (en) | Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis | |
| JP2005505537A (ja) | 低分子量ヘパリンと低分子量デルマタン硫酸とを含む抗血栓組成物 | |
| AU2002351915B2 (en) | Uso of specific dose of fondaparinux sodium for the treatment of ACS | |
| Sidell | Modification by diluents of effects of intramuscular atropine on heart rate in man | |
| AU2002351915A1 (en) | Uso of specific dose of fondaparinux sodium for the treatment of ACS | |
| Hyers | Heparin therapy: regimens and treatment considerations | |
| Levine et al. | 4 Clinical potential of low molecular weight heparins | |
| Trial | Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis | |
| Åberg-Wistedt et al. | Lithium and renal function in relation to concomitant theory | |
| Prandoni | Current status of the clinical use of heparin fractions | |
| EP1321152A1 (en) | Antidote for org 31540/SR 90107A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status | ||
| FG | Grant or registration |